ESC Medical Systems raises $18 million in secondary offering:
This article was originally published in Clinica
Executive Summary
ESC Medical Systems has raised $18 million net in a secondary public offering five months after going public. The electro-optic device developer sold 750,000 shares at $24.75 each at the same time as stockholders offered 3 million shares. ESC, based in Haifa, Israel, floated on the Nasdaq in January at a price of $15 a share (see Clinica No 687, p 9 and No 691, p 15).
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.